K

KeyMed Biosciences Inc
HKEX:2162

Watchlist Manager
KeyMed Biosciences Inc
HKEX:2162
Watchlist
Price: 58.1 HKD 0.26%
Market Cap: 17.4B HKD

KeyMed Biosciences Inc
Interest Income Expense

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
TTM
|
See Also

KeyMed Biosciences Inc
Interest Income Expense Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Interest Income Expense CAGR 3Y CAGR 5Y CAGR 10Y
K
KeyMed Biosciences Inc
HKEX:2162
Interest Income Expense
¥82.8m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Beigene Ltd
HKEX:6160
Interest Income Expense
¥44.5m
CAGR 3-Years
N/A
CAGR 5-Years
0%
CAGR 10-Years
N/A
Innovent Biologics Inc
HKEX:1801
Interest Income Expense
-¥155.5m
CAGR 3-Years
N/A
CAGR 5-Years
-23%
CAGR 10-Years
N/A
Akeso Inc
HKEX:9926
Interest Income Expense
¥174.2m
CAGR 3-Years
115%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Beijing Wantai Biological Pharmacy Enterprise Co Ltd
SSE:603392
Interest Income Expense
¥204.9m
CAGR 3-Years
214%
CAGR 5-Years
68%
CAGR 10-Years
N/A
S
Sichuan Kelun-Biotech Biopharmaceutical Co Ltd
HKEX:6990
Interest Income Expense
¥69.7m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

KeyMed Biosciences Inc
Glance View

Market Cap
17.3B HKD
Industry
Biotechnology

In the bustling city of Chengdu, China, amid the rise of modern medical innovation, KeyMed Biosciences Inc. has emerged as a prominent player in the biotechnology sector. Established by a team of experienced scientists and industry veterans, the company focuses on the discovery and development of novel biologic therapies aimed at addressing critical unmet medical needs, particularly within the oncology and autoimmune disease spaces. With its proprietary technology platforms, KeyMed drives its research and development by leveraging extensive capabilities in monoclonal antibody discovery and engineering. This approach allows the company to create innovative products that potentially offer superior efficacy and safety profiles compared to existing treatments, thus underpinning its mission to contribute significantly to global healthcare advancements. KeyMed Biosciences operates on a business model primarily centered around product development pipelines, strategic partnerships, and licensing agreements. The company's revenue streams are chiefly generated from licensing out its proprietary drug candidates and technologies to major pharmaceutical companies, who seek late-stage and commercialized assets. These collaborations not only provide the financial means necessary to fuel ongoing R&D but also facilitate accelerated development timelines and expand the reach of their therapeutic innovations. Furthermore, as these candidates progress through clinical trials and receive regulatory approvals, KeyMed stands to gain from milestone payments and, eventually, a share of sales revenues. This symbiotic relationship between cutting-edge research and astute financial strategies defines KeyMed's path forward in a competitive industry landscape.

KeyMed Biosciences Inc Intrinsic Value
HIDDEN
Show

See Also

What is KeyMed Biosciences Inc's Interest Income Expense?
Interest Income Expense
82.8m CNY

Based on the financial report for Dec 31, 2024, KeyMed Biosciences Inc's Interest Income Expense amounts to 82.8m CNY.

What is KeyMed Biosciences Inc's Interest Income Expense growth rate?
Interest Income Expense CAGR 1Y
7%

Over the last year, the Interest Income Expense growth was 7%.

Back to Top